The nationwide DANBIO registry has been designed to capture operational clinical data as part of routine clinical care. At the same time, it provides a powerful research database. This article reviews the DANBIO registry with focus on problems and solutions of design, funding and linkage, provides an overview of the research outcome and presents the cohorts of RA patients. The registry, which is approved as a national quality registry, includes patients with RA, PsA and AS, who are followed longitudinally. Data are captured electronically from the source (patients and health personnel). The IT platform is based on open-source software. Via a unique personal identification code, linkage with various national registers is possible for research purposes. Since the year 2000, more than 10 000 patients have been included. The main focus of research has been on treatment efficacy and drug survival. Compared with RA patients, who were on conventional treatment with DMARDs, the patients who started biological treatment were younger, had longer disease duration, higher disease activity, tried more DMARDs and received more prednisolone. Also, more patients on biological therapy were seropositive and had erosive disease. However, the current levels of disease activities and the fraction of patients who had gone into remission in the two groups of patients were very similar. This indicates that clinicians have a common treatment goal for RA patients regardless of treatment. In conclusion, DANBIO serves as an electronic patient 'chronicle' in routine care, and at the same time provides a powerful research database.
Introduction
Real-life data are important in improving clinical decision-making both for the individual patient and in general. Establishing a clinical register has the potential to improve outcome in the individual patient, it can promote better quality of treatment in general, and data can be analysed to answer important clinical research questions. DANBIO differs from many databases in several aspects. Importantly, it has been designed to capture operational clinical data as part of routine clinical care. Without additional work for the clinician, it offers a clinically useful service with immediate access to well-presented longitudinal patient records, while at the same time providing a powerful research database. For patients and clinicians, registration has proved helpful rather than a hindrance.
Ten years ago, the DANBIO registry was established. It soon gained wide acceptance and, as of today, more than 10 000 patients with inflammatory rheumatologic diseases have been included and, followed longitudinally.
The aim of this article was to review the DANBIO registry with emphasis on how a national database with expedient design and data output was designed, as well as to provide an overview of the research outcome. The review will cover the following topics: aim, history, organization and funding, ethical and legal aspects, DANBIO as a national quality registry, open source IT platform, linkage to other registries, treatment regimens, data collection and quality, research outcome and presentation of the RA cohorts.
The Danish DANBIO registry provides nationwide data on the disease course of patients with inflammatory rheumatic diseases that are treated in routine care.
Since 2005, the aim of the registry has been 2-fold: to be a powerful research database on, for example, treatment effectiveness, adverse events and quality of life, while simultaneously providing a helpful tool in the consultation by providing a disease chronicle for the rheumatologist to improve the quality of clinical care.
In parallel, the Danish authorities have given priority to the establishing of national quality registries that monitor a number of quality indicators in selected diseases, and RA has been selected as one such. This has significant implications, which are discussed later in this article.
History
As was the case in most other countries, Denmark had no routine-based registration of RA patients on a wider scale up to the year 2000, and patient files rarely comprised quantitative outcomes, e.g. health assessment outcomes (HAQ) scores or swollen-joint counts (SJCs). Inspired by other registries in Europe [1] [2] [3] [4] [5] , the marketing of the first TNF-a blockers, etanercept and infliximab, triggered the formation of a nationwide voluntary registry, which aimed to survey indications for treatment, efficacy and adverse events in rheumatologic patients who were started on biological therapies. The registry was named The Danish Registry for Biologic Therapies in Rheumatology. For convenience, the name was later changed to DANBIO, although the formal name is DANBIO-DRD (DRD being an abbreviation of Danish Rheumatologic Database).
In the early years, data were collected on paper forms, which were subsequently scanned into the database at the DANBIO office [6] . At irregular intervals, data were returned to the rheumatologist in the format of paper graphs showing the changes over time in, for example, 28-joint DAS (DAS-28). This feedback was received very positively by the users, and the idea of developing an online version with immediate access to patient data was born. With the introduction of DANBIO-online in 2005, the aims were extended to also encompass a sort of electronic patient record (EPR), and in parallel to be a national quality database monitoring rheumatologic patients.
A central initiative in the transition from paper-based surveillance into an electronic registry that included all patients regardless of treatment, was a PhD study on health-related quality of life (HR-QoL) that aimed at including as many RA patients as possible, regardless of treatment [7] . Tailored paper forms for the project were developed, which made registration of large numbers of new patients in DANBIO feasible to the physicians. Several departments used this opportunity to include all RA patients. This initiative resulted in a massive influx of DMARD-treated patients (Fig. 1) . Thus, between 2005 and 2007 about 3000 DMARD-treated patients were entered into the registry.
The almost concurrent introduction of a user-friendly web-based solution, which was introduced at no costs to the departments across the country in 2005 (www.danbio-online.dk) [8] , kickstarted the use of the registry as an EPR in the routine care of both biological and non-biologic patients. During a transitional period of <2 years, the use of paper forms quickly died out.
As of 31 December 2009, 4061 RA patients initiating therapy with biological agents and 4772 DMARD-treated RA patients had been included in the registry (Fig. 1 ). In parallel with RA patients, patients with AS and PsA were also included-initially only those on biological treatment, later also including patients on other treatments. A total of 1049 AS patients on biological and 204 on conventional treatment, respectively, had been registered by 31 December 2009 [9] . For patients with PsA, the corresponding numbers were 843 and 464, respectively. The inclusion of new patients continues. 
Organization and funding
DANBIO has an independent steering committee with representatives from the Danish Society of Rheumatology, the Institute for Rational Pharmacotherapy and the hospital owners. It handles the regulatory, practical, financial and scientific challenges of the registry. DANBIO is sponsored by the hospital owners (Danish Regions) and by the pharmaceutical companies that offer biological treatments in rheumatology (Abbott, Bristol Myers Squibb, Roche, MSD, UCB-Nordic, Pfizer). The sponsors have no influence on the registry set-up, data collection, data analysis or publication of results. These issues are all administered by the steering committee. The independence of individual pharmaceutical companies by including all relevant companies is regarded as a strength. All sponsor contracts are approved by the legal department of the hospital owners in the Copenhagen Region (which is where the registry is located).
Ethical and legal issues
According to the Danish laws, no ethical approval is needed for the publication of research data that are based on routine collection of data. Projects involving linkage to other registries or biobanks, for example, require ethical approval. The registry is approved by the Danish Data Protection Agency, which is based on the Act on Processing of Personal Data ensures that data security, protection of individual rights, etc. are dealt with correctly.
DANBIO as a national quality registry DANBIO has been approved by the National Board of Health as a national quality registry since 2006, after which the reporting to the registry became mandatory. This has significant implications for the DANBIO registry. Most important is perhaps that the usual requirement for obtaining an informed consent from the patient before registration can be done does not apply to registries that are approved by the National Board of Health as a National Quality Register. This has beyond doubt reduced bureaucracy and lowered the threshold for registration. Only rarely do patients object to registration, and, in these cases, it is up to the physician to decide whether to register the patient or not. Furthermore, registration in a National Quality Register is mandatory for the health personnel (however, with no explicit sanctions for those who do not register!), and the registers receive financial support from the hospital owners sufficient to cover some expenses. The Danish Rheumatologic Society has set up national indicators for quality goals in the treatment of RA. The monitoring of these indicators is based on DANBIO. The performance of each department is published in an annual report, which is published in Danish on www .danbio-online.dk/formidling. In addition, the search module in the registry will in the future allow for the individual physician to compare with national practice.
Open source information technology platform
The information technology (IT) platform of DANBIO is entirely based on so-called Open Source software, which is developed and supported by worldwide computer science communities, and is available at no license costs in terms of use, customization for specific needs and sharing with other clinical databases. The most important software in use is the web application platform Plone (www.plone.org/Plone Foundation), the language for statistical programming R (www.r-project. org/R Foundation), the database MySQL (www.mysql. org/MySQLAB) and the general computer language Python (www.python.org/Python Foundation). MySQL, Python and R are used both in the data processing and statistical analysis on the DANBIO desktops. DANBIO's use of an open source IT platform has proven successful in integrating the research process and the clinical work at the hospitals, and has become an important tool in the continuous process of building a collaborative research network. The DANBIO IT platform has been shared with other registries, e.g. ICEBIO (Iceland's biologics register), SCQOM (The Swiss biologics register) and Euromyositis (The European myositis register).
The IT solution has a flexible structure that allows for future expansion, e.g. adding diagnoses and outcomes as well as new drugs. Thus, DANBIO-online has been improved and expanded with new versions being launched approximately every other year.
The IT platform is placed on a server. This has the practical consequence that no installation of software programs at individual computers is needed, and updates on software are easily implemented at low costs. The solution requires a secured broadband Internet connection. The server has a backup, which will replace the server in the case of a breakdown.
Linkage to other registries
Every Danish citizen has a unique personal identification number, which follows him or her from birth to death. All events in an individual's life that are associated with public expenses are being registered by this code. This enables linkage (after regulatory approval for specific research purposes) between DANBIO and, for example, the national cancer registry, the hospitalization registry, the death registry and pension registries. This enables the potential to answer questions that other registers fail to address, such as the safety of biologic drugs in the male partner of conceiving parents.
The system offers the opportunity to electronically forward the suspected adverse drug reactions (ADRs) that are reported to the registry (automatically entering the required additional information) to the Danish Medicines Agency, to which reporting of suspected ADRs is mandatory during the first 2 years of post-marketing use. Reporting of definite ADRs is mandatory at any time.
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Treatment regimes
In Denmark, all biological treatments in rheumatology are prescribed and administered in secondary care (at the departments of rheumatology). National guidelines for the treatment with biological drugs were issued in year 2000 (Table 1) , and updated by the DANBIO steering committee in 2006 (Table 2 ). In brief, a DMARD (preferably MTX) is the first drug of choice, and should be prescribed in highest tolerated dosage (up to 25 mg weekly) with concomitant folic acid supplementation. Only in cases that are MTX resistant (active disease with DAS-28 > 3.2, progression of radiographic erosions or continuous need for prednisolone >7.5 mg daily) despite MTX treatment should biological treatment be considered. The drug costs are reimbursed by the public health system, and although some regional differences have been reported, the access to treatment is considered to be better than in most other countries [8] . Baseline data regarding disease activity are considered valid, since the treatment criteria are widely accepted among rheumatologists and patients.
The treatment regimens reflect routine care. Before biological treatment initiation, patients are screened for tuberculosis, hepatitis, etc. according to local guidelines. The biological drugs are prescribed in standard dosages, unless the rheumatologist decides otherwise. Dose escalation or reduction by changing of intervals or dosage is allowed. For all drugs, it is recommended to treat in combination with MTX, although some may be administered as monotherapy. Choice of biological drug as well as concomitant treatment with other DMARDs or prednisolone is made according to the national and local guidelines. The rheumatologist records information on type of drug, start and stop dates (date of first missed dose) and reasons for withdrawal, and reports adverse events in a standardized form at each medical visit.
Data collection
Points to consider in the establishing of a registry have been addressed thoroughly in a recent publication [10] . In DANBIO, data are captured electronically from the source, requiring only little instruction of the patients and professionals. DANBIO has developed dedicated touch screens where patients enter data on, for example, disability, pain, lifestyle and HR-QoL, in the waiting room (Fig. 2) . The validity of touch screens in comparison with paper forms was investigated, and the two modalities were shown to perform equally well [11] . The information from the touch screen is available in the consultation, e.g. all HAQ questions and visual analogue scale (VAS) scores are presented in one screen image, which represents a good base for a discussion of health status between the patient and the nurse/physician. During the consultation, nurses, rheumatologists and other health-care professionals add data on, for example, joint counts, medications and adverse events on their computers.
Patient data can only be accessed by health professionals by an individual log-on to the system, and all activity on the site is being logged electronically and can be traced, if needed.
Compared with a paper-based registry, the electronic solution eliminates double work and reduces the risk of [25] . Active disease (DAS-28 > 3.2) or . progression of radiographic erosions or . continuous need for prednisolone >7.5 mg daily . despite optimal treatment with DMARD errors. Data entry takes a few minutes, but the users report that the time spent on data entry is regained during the consultation, because they get immediate access to a well-presented longitudinal electronic patient record; a kind of disease chronicle that gives an overview and improves clinical decision-making during the visit (Fig. 3) . The so-called scoreboard presents the treatments and disease activity variables including the DAS-28 score over time, with colours (red = severe disease activity, DAS-28 > 5.2; yellow = moderate disease activity; green = low disease activity, DAS28 < 3.2) that have proved very useful for both patients and professionals.
The DANBIO register covers patients with RA, AS and PsA. The patient's diagnosis defines which variables are visible at the user interface. Thus, only patients with axial disease (AS or PsA) fill out the BASDAI, BASFI and   FIG. 3 The scoreboard presents individual patient data at a glance. FIG. 2 Examples of touch-screen questions to be answered by the patient in the waiting room.
www.rheumatology.oxfordjournals.org BASMI. The variables that are collected are presented in Table 3 . Basically, there are two types of variables: baseline (fixed) variables, e.g. demography (date of birth and gender), diagnosis, date of diagnosis; and follow-up/ longitudinal variables that change over time, e.g. treatment and disease activity. Patients are followed longitudinally with at least two annual visits. This is not mandated by the research need, but to the third aim of the registry: being a quality database, i.e. documenting that treatment is being sufficiently monitored by the treating physician. In addition, non-routine visits can be registered, e.g. in case of flare where intra-articular injections or treatment adjustments may be needed. To avoid biases for research, these visits are flagged as acute visits.
X-rays of hands, wrists (posterior-anterior projections) and forefeet (anterior-posterior view) are taken at baseline (start of treatment) and repeated annually for 2 years and when switching of therapy. Information on X-rays (date and description) is entered into the registry. In an ongoing research project, digitized X-rays have been Sharp scored and plans for the future include linkage of the images to the registry. The registration of serious adverse event (SAE)s is similar to clinical trials: an adverse event is serious if it results in death, life-threatening events, disablement, hospitalization, malignancy or birth defect, and the rheumatologist judges whether an SAE is an ADR by classification into definite, probable, possible or probably no relation to the drug.
Data quality
It is a continuous challenge to achieve and maintain valid and complete data. The variables are collected in a standardized format, often using tick boxes, which have high validity [6] . Each field has a predefined range of acceptable answers, if, for example, a tender joint count (TJC) of 30 is entered, an error message pops up. The majority of variables are not mandatory. Blank fields will result in an incomplete score board (Fig. 3) , which is unsatisfying for patient and physician. The user-interface thus motivates the physician to complete all core fields, but in a non-punitive manner. In connection with queries from DANBIO and research projects, the departments fill in missing data by checking against the hospital patient records. Data completeness is in general high (https://danbio-online.dk/formidling). Coverage is assessed annually by comparing patients in the registry with those registered in each department of rheumatology. In 2009, it was 92% for biologically treated patients. Patients are, in principle, followed life-long in the registry but, in reality, registration often ceases when the patient is withdrawn from therapy. The DANBIO secretariat sends out queries if a patient has not been registered the previous 6 months and collects information on date of, and reason for, withdrawal.
Data from each visit are stored as a sort of electronic patient file, which can also automatically be converted to a text document, if a paper record is needed. This has improved the quality of patient notes, and reduced the workload for secretaries who can instead assist with data entry. Data are simultaneously exported to the national DANBIO research database for research purposes.
The system is also being used as an electronic case record form (CRF) in clinical trials, where additional variables may be introduced, and data can be exported in any format for research purposes. When data are exported, the patients are anonymized by replacing the personal identification code with a serial number. Research associated data entry is only done by the physicians who are investigators in the specific trial, and the additional fields are only visible for them via the individual log-on.
A system has been set up for a semi-automated generation of data output. In a few seconds, any user can make queries into his/hers patients, e.g. number of patients with RA who at the latest visit had more than two swollen joints while on the third biological drug, or queries that identify patients with missing data, e.g. CRP, missing visits, etc. The flexible search can also be used for audits (e.g. whether guidelines are followed) and to quality improvement initiatives (comparison of own department with the rest of the country).
Research outcome
A main focus of the research on DANBIO data has so far been on drug efficacy. A direct comparison of the three TNF inhibitors showed significant differences in efficacy [12] . Infliximab had the lowest rates of treatment response, disease remission and drug adherence, adalimumab had the highest rates of treatment response and disease remission and etanercept had the longest drug survival rates. These findings were consistent after correction for confounders and sensitivity analyses and across outcome measures and follow-up times. Other data from DANBIO conclude that the response rates to biological therapy have improved year-by-year since the marketing of the first biological drugs [13] . This was remarkable, because the improvement in response was observed despite a concurrent drop in disease activity in patients who initiated therapy. The improved treatment response may be associated with an increased dose of concomitant MTX. The finding contrasts other reports that patients treated outside clinical trials should respond less to treatment due to less severe disease activity [14, 15] . It was also shown that the prescription practice in Denmark and Norway became less stringent during the first years of the biologics' era [8] . Almost half of the Danish and Norwegian patients that started biological treatment did not meet the UK criteria for treatment [8] . DANBIO data have also been published on the impact of switchingshowing that switchers have good treatment response whether they switched due to lack of efficacy or adverse events to the first biologic, and for the switchers, the drug survival rate was higher for the second than for the first TNF inhibitor [16] .
HR-QoL is not often registered as part of routine care. Data from DANBIO showed that the validity of a number of HR-QoL instruments was good [17] . Several clinical and demographic variables that may bias the HR-QoL were identified [18] , and HR-QoL was found to be significantly impaired in RA patients, but almost normalized in patients in clinical disease activity index (CDAI) remission [7] .
Most recently, DANBIO has published efficacy and drug survival data on AS and PsA patients treated with biologics [9, 19] , as well as data on the radiographical impact of TNF inhibitor treatment in routine care [20, 21] .
Data from DANBIO also demonstrated that during the first years of biological treatment, drug survival was high despite low remission rates [22] , and how a routine-based registration increased the reporting of adverse events several-fold in comparison with the mandatory reporting to the Danish Medicines Agency [6] . Other researchers have published studies in which DANBIO was used as an electronic CRF for the clinical data [23, 24] .
Similarities and differences between DMARD-and biologically treated patients with rheumatoid arthritis Table 4 shows the status of the RA patients that were on biological or DMARD treatments, respectively, in 2009. The patients who started on biological treatments were significantly younger, but also had much longer disease duration than patients on DMARD therapy (7.9 vs 5.3 years, respectively). They had tried more DMARDs, and prednisolone use, seropositivity and erosive disease were more prevalent. The patients that started on biological treatment had thus, as expected, more severe disease. This was reflected in the disease activity level at the start of biological treatment, which was higher both regarding the number of swollen and tender joints, CRP and VAS scores for pain, fatigue and global in comparison with the DMARD-treated patients. The selection of patients for biological treatment was in accordance with the national guidelines regarding initiation of biological treatment in RA patients. Interestingly, the current levels of disease activity were very similar between the two groups regarding DAS-28 scores, VAS scores, number of swollen and tender joint counts as well as the fraction of patients in the two groups who had gone into remission. This suggests that clinicians had a common treatment goal for RA patients, regardless of treatment modality.
Conclusion
In conclusion, DANBIO is a nationwide registry, which provides real-life data that improve clinical decision-making. At the individual level, it serves as an electronic patient file and it also serves as a national quality registry. At the same time, without additional work for the clinician, it provides a powerful research database that has published research on, for example, the efficacy and drug survival of biological treatments in patients with RA, AS and PsA.
Rheumatology key messages
. DANBIO has been designed to capture operational data as part of routine clinical care. . DANBIO is nationwide and includes patients with RA, PsA and AS, regardless of treatment. . DANBIO has published data on biological treatments regarding, for example, drug efficacy and drug adherence in clinical practice.
